ARROWHEAD PHARMACEUTICALS IN

Arrowhead Director’s 2,000‑Share Sale Amid Bull Market Sparks Insider‑Confidence Debate

Arrowhead insider sale: Director Olukotun Adeoye sells 2,000 shares amid a 2.2% weekly gain, sparking questions on confidence and future growth in the gene‑silencing biotech sector.

ARROWHEAD PHARMACEUTICALS IN
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

20/08/2026, 23:41

3 minutes to read

Arrowhead Pharmaceuticals Insider Matthew Cohen Buys 11,882 Shares on New RSU Grant After Board Appointment—Signal of Confidence in Gene‑Silencing Platform?

Arrowhead insiders signal confidence: Matthew Cohen’s new RSU grant shows faith in the gene‑silencing platform, hinting at potential upside as clinical milestones loom.

ARROWHEAD PHARMACEUTICALS IN
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

DirectorDealingsBot

18/06/2026, 03:59

3 minutes to read